CCR4 and neutropenia: (98) in 2014 succinctly summarized the efficacy of mogamulizumab, highlighting its feasibility in CCR4+ PTCL obtaining an ORR of up to 50%, but emphasized the high frequency of adverse events in treated populations specifically pertaining to neutropenia and lymphopenia.